Mechanisms of immune checkpoint inhibitors

Mechanisms and Management of Immune Checkpoint Inhibitor ...

The manifestation of cardiac irAEs includes myocarditis, arrhythmias and conduction abnormalities, and pericardial diseases.

Full article: A landscape of checkpoint blockade resistance in cancer

In physiological conditions, the main function of Tregs is to maintain immune homeostasis; however, cancer exploits Treg cellular mechanisms to restrain the ...

Mechanisms of hyperprogressive disease after immune checkpoint ...

Immune checkpoint inhibitors (ICIs) have made a breakthrough in the treatment of different types of tumors, leading to improvement in ...

Immune-Checkpoint Inhibitors-Induced Type 1 Diabetes Mellitus

Effect of immune-checkpoint inhibitors on T lymphocytes. Anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA4) blocking and anti-programmed ...

Mechanisms of action of immune checkpoint inhibitors Binding of PD ...

Download scientific diagram | Mechanisms of action of immune checkpoint inhibitors Binding of PD-L1 to its receptor can suppress T cell migration, ...

A Newly Uncovered Mechanism Underlying Resistance to Immune ...

Immune checkpoint inhibition is a form of cancer immunotherapy that works by releasing the “brakes” on the immune system, thereby increasing ...

Immune checkpoint inhibitors in breast cancer - OAE Publishing Inc.

Antigen presentation · Antibody-drug conjugates. Similar to the rationale for combining ICIs with chemotherapy which was discussed earlier, ...

Mechanisms of checkpoint inhibition-induced adverse events

Summary. Immune checkpoint inhibition has revolutionized the treatment of several solid cancers, most notably melanoma and non-small-cell lung cancer (NSCL.

Mechanisms of immune-related adverse events during the treatment ...

Immune checkpoint inhibitors are novel biologic agents to treat cancer by inhibiting the regulatory inter- actions that limit T cell cytotoxicity to tumours.

Mechanisms of primary resistance to immune checkpoint inhibitors ...

Conclusions. In conclusion, primary resistance to ICIs in patients with NSCLC is not fully elucidated. It includes several mechanisms creating a ...

Mechanism of cancer treatment of immune checkpoint inhibitor therapy

Checkpoint inhibitor therapies are therapies that release immunosuppression by removing signals that inhibit T cell activation/activity. When activated by a “ ...

Immune Checkpoint Therapies and Atherosclerosis - JACC Journals

Immune checkpoint inhibitors enhance tumor cell killing by targeting PD-1, PD-L1, and CTLA-4 to restore T-cell activation and inflammatory ...

Biological mechanisms of resistance to immune checkpoint ... - OUCI

Immune checkpoint inhibitors have opened up new possibilities in clinical oncology. Monoclonal antibodies have shown their high clinical efficiency.

Immune checkpoint inhibitors: A strategy to tackle cancer? - genOway

Immune checkpoints are expressed on many tumor cells, allowing them to cleverly evade host immune response and divide uncontrollably.

Mechanisms and clinical manifestations of cardiovascular toxicities ...

Immune checkpoint inhibitors (ICI) can cause a wide range of inflammatory side effects called immune-related adverse events (irAEs). These toxicities can affect ...

Immune checkpoint inhibitors in malignancy - Australian Prescriber

Inhibiting the immune checkpoints reduces the body's ability to dampen the immune response. This causes a marked increase in immune-mediated ...

Immune Checkpoint Inhibition—Does It Cause Rheumatic Diseases ...

Mechanisms of immune checkpoints and their role in autoimmunity are discussed in the context of immune checkpoint inhibitor (ICI) therapy for cancer.

Clinical spectrum and evolution of immune-checkpoint inhibitors ...

Immune-checkpoint inhibitors (ICI) have revolutionized cancer therapy, providing unprecedented responses in a wide range of malignancies but they can lead to ...

Hematologic complications of immune checkpoint inhibitors | Blood

Putative mechanisms of immune checkpoint inhibitor–associated hematologic toxicities. Anti–CTLA-4 therapy blocks inhibitory signals to cytotoxic ...

a mechanism of acquired resistance to anti-PD-1 therapy in ...

Heterogeneity in mechanisms of resistance to immune checkpoint inhibitors in individual patients, as observed in the current study, highlights the difficulties ...